Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
Presented at this week’s European Congress on Obesity, the two studies also demonstrate that Novo Nordisk’s Wegovy ...
A recent US study has found that weight loss medications like Wegovy and Ozempic may increase the risk of abdominal paralysis ...
Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk’s case to insurers and governments to ...
A Novo spokesperson said in a statement to Reuters that the new analysis "demonstrates for the first time the benefits of ...
The anti-diabetic medication “Ozempic” (semaglutide) made by Danish pharmaceutical company “Novo Nordisk”on February 23, 2023 ...
Wegovy, a relatively new drug approved by the US Food and Drug Administration (FDA) in June 2021, mimics the body’s GLP-1 ...
The data could go some way to convince insurers and governments to reimburse Wegovy. Read more at straitstimes.com.
Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...
Patients sometimes have to stop using GLP-1 medications like Ozempic and Wegovy and risk regaining lost weight.
Global spending on obesity medications totaled $24 billion last year, IQVIA estimated in its latest five-year outlook, and ...